Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glucose homeostasis modeling under dapagliflozin in type 2 diabetes
jRCTs051180058Completed
- Sponsor
- AstraZeneca
- Start
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of dapagliflozin in type 2 diabetes mellitus (T2DM), sponsored by AstraZeneca. Primary endpoint: Parameter calculated from mathematical model. Started Jul 2017; status: completed.
02
Drugs
dapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCTs051180058.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051180058.